Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

Vista PD is a randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy. The main objectives of this clinical trial are to determine the following: * Does VIM0423 therapy improve tremor symptoms in adults with Parkinson's disease? * Is VIM0423 well tolerated in individuals with Parkinsons's disease? and * Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?

Participants needed: 80
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Vima TherapeuticsUpdated: Sep 11, 2026Locations: 30
Eligibility criteria

Participant must be male or nonpregnant female between 18 and 65 years of age (i... [+3]

Currently (within 7 days of Screening) taking any anticholinergic medication. [+1]

Status: Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia

Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia. The main objectives of this clinical trial are to determine the following: * Does VIM0423 therapy improve dystonia symptoms compared to placebo? * Is VIM0423 well tolerated in individuals with isolated dystonia? and * Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?

Participants needed: 100
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Vima TherapeuticsUpdated: Sep 15, 2026Locations: 38
Eligibility criteria

Participant must be male or nonpregnant female between 18 and 70 years of age (i... [+3]